January 27th, 2024 - A briefing document from the FDA for the Cellular, Tissue, and Gene Therapies Advisory Committee Meeting entitled, “Toxicity Risks of Adeno-associated Virus (AAV) Vectors for Gene Therapy” (September 2021), recognizes the importance of incorporating NxGEN’s Transformative Technology into AAV vectors to evade the immune system for durable transgene expression.

The contribution of CpG dinucleotides in the vector genome in activating the innate immune mechanisms upon cellular entry is first mentioned on page 14 of the briefing. Section 2.4.2 goes into more detail on TLR9-dependent immune induction and recommends “codon modification to remove CpGs” as a strategy to circumvent CpG-mediated immune activation (page 16). 

Click here to read the Briefing Document

November 23rd, 2023 - NxGEN Vector Solutions attended the Washington Post Improving Patient Care live event program, at the Post’s D.C. headquarters.

This exclusive invite only event was a Symposium featuring panel conversations on the state of the U.S. Health Care System, the cost of prescription medication, and the ways to improve the patient experience hosted by Senator Susan Collins, Senator Jeanne Shaheen, Avik Roy, Matthew Fiedler, and Davis Liu.

September 27th, 2023 - NxGEN Vector Solutions attended the Washington Post Entrepreneurial Resilience live event program, at the Post’s D.C. headquarters. 

This exclusive invite-only event was a series of discussions about challenges and opportunities for small businesses in today’s economic climate.

June 6th, 2023 - NxGEN is excited to announce that we have won a Biotechnology award from Global Health and Pharma (GHP).

We have been awarded the Most Advanced Gene Therapy Vector Technology Company 2023.

April 21st, 2023 - Partner with NxGEN Vector Solutions to apply NxGEN Technology to your AAV vectors and eliminate the immune response that limits transgene durability.

Learn more about NxGEN’s technology to reduce the body’s immune reaction toward your AAV vectors, leading to safe, effective, and durable therapeutic gene expression in the Cell and Gene Therapy Supplement of Genetic Engineering & Biotechnology News (GEN) Magazine below.

Click here to read the article

February 14th, 2023 - Read Dr. Faust’s Journal of Clinical Investigation scientific publication from 2013 demonstrating that CpG-depleted AAV vectors can establish persistent transgene expression, evade immunity, and minimize infiltration of effector cells following gene transfer.

Dr. Faust is a pioneer in this research and was the first to CpG-deplete AAV vectors to circumvent TLR9 activation, a technology that has become an industry standard.

Click here to read the article

December 8th, 2022 - NxGEN Vector Solutions is featured in December’s issue of GEN Magazine in the article, “Viral Vectors for Gene Therapy Get the Industrial Design Treatment.”

Read about both of NxGEN’s gene therapy platforms:

1) NxGEN’s CpG-depletion technology of the AAV vector to achieve safe, effective, and durable
therapeutic gene expression.

2) NxGEN’s cardiac gene therapy to modulate the immune system to prevent chronic rejection without
the requirement for life-long anti-rejection medication, which can also be used for inflammatory

Click here to read the Article in GEN Magazine.

November 1st, 2022 - Dr. Susan Faust is an invited guest speaker at the Global Bioprocessing Summit & Exhibition in San Francisco from November 2-4, where she will be presenting her talk entitled: Hindsight is 2020: The Advancement of CpG-depleted AAV Vectors as an Industry Standard.

September 1st, 2022 - NxGEN Vector Solutions hit a major milestone this year: We are celebrating 5 years in business! A big thank you to all of our customers!

NxGen Vector Solutions

June 1st, 2022 - The NxGEN Vector Solutions Team at ASGCT